• Also Known As:
  • TB
Medically Reviewed by Expert Board

This page was fact checked by our expert Medical Review Board for accuracy and objectivity. Read more about our editorial policy and review process.

This article was
last modified The modified date indicates that one or more changes were made to the article. Such changes may or may not result from a full review of the article, so the two dates may not always agree.

What is tuberculosis?

Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis. TB primarily affects the lungs (pulmonary TB). Other parts of the body may become involved as well, however, either as part of the initial infection or, more commonly, as part of a late widespread infection.

TB is spread when a person with active, infectious TB disease coughs, sneezes, or spits, releasing droplets containing TB bacteria into the air, which are then inhaled by someone else. A single cough from a person with active pulmonary TB may contain 3,000 droplets with TB bacteria. If as few as 10 of those bacteria are inhaled by someone nearby, that person can become infected. An individual with active pulmonary TB disease may infect 10-15 other people through close contact over the course of a year.

Not everyone who is exposed to TB bacteria will develop an infection, and not all of those who become infected will develop symptoms of TB disease. Those who are infected but have no symptoms are said to have a latent TB infection. Those who do become sick have an active infection.

  • People with latent TB usually have strong natural defense (immune) systems that prevent the TB bacteria from multiplying. They do not have TB symptoms and cannot spread TB to others. It is possible, however, for a person with a latent infection to develop an active infection in which TB bacteria are “reactivated” and start multiplying. This happens to about 10% of people with untreated latent TB infections who are otherwise in good health. A greater percentage of people with compromised immune systems, such as those suffering from malnutrition, tobacco users, those with diabetes, and especially those with HIV infection, will develop active TB disease.
  • An active TB infection means the TB bacteria are multiplying, either in the lungs or elsewhere in the body. This will cause a person to have symptoms of TB disease. Active TB is highly contagious.

Both latent and active TB can be treated and cured with a combination of antibiotics that must be taken for several months. Without treatment, active TB disease may cause serious illness or even death.

TB has been a leading cause of death for thousands of years. In the days before the discovery of antibiotics, it was called consumption, and those who contracted it were put into long-term hospitals called sanatoriums for the rest of their lives. Although its frequency has decreased dramatically in the United States, the World Health Organization (WHO) estimates that one-third of the world’s population has latent TB. Worldwide, active TB disease is the most common cause of infectious disease-related death, especially among those who are living with HIV, killing about 1.5 million people a year.

In the U.S., there were more than 9,400 reported cases of TB in 2014. This represents about 2.6 cases per 100,000 persons, the lowest recorded since reporting began in 1953. There was resurgence in new cases in the early 1990s, but the rate of TB infections has been steadily declining since then. Nevertheless, certain populations within the U.S. are at higher risk of infection. These include:

  • International travelers
  • African Americans continue to be disproportionately affected.
  • Those living in correctional facilities and other group living situations
  • The homeless

While the numbers of new cases of active TB have again declined in the U.S. due to constant vigilance by the medical community, TB remains a significant national and global public health problem.

One of the many challenges in managing TB worldwide is the number of new cases that are cannot be cured with the standard antibiotics used to treat the disease. This is known as multidrug-resistant tuberculosis (MDR-TB).

  • Inappropriate or incorrect use of the standard antibiotics, or use of poor quality medicines, can cause MDR-TB.
  • Once identified, MDR-TB can be treated and cured using a different combination of antibiotics. However, these “second-line” treatment options are limited and the recommended antibiotics may not be always available. Second-line therapeutic agents require a longer course of treatment (up to 2 years) and are more costly than standard treatment regimens, and the drugs may be associated with more severe adverse side effects.
  • Some cases of TB are resistant to even the most effective second-line anti-TB drugs. This is known as extensively drug-resistant TB (XDR-TB) and is an emerging public health concern. XDR-TB has been defined by WHO and the U.S. Centers for Disease Control and Prevention (CDC) as M. tuberculosis that is resistant to the drugs isoniazid and rifampin, to the drug class fluoroquinolone, and to at least one of three injectable “second-line” drugs (amikacin, kanamycin, or capreomycin). Cases of XDR-TB are being closely monitored by the world medical community and measures are being taken in hopes of limiting its spread.


About Tuberculosis

Risk Factors

Not everyone who is exposed to TB will become infected, and not everyone who has a latent infection will develop an active infection. The timeframe for greatest risk of progressing to active disease is within the first year after contracting the infection. Those who are at a greater risk of developing active TB include:

  • People who are in close contact with someone who has active TB disease
  • Immigrants from areas of the world where the incidence of TB is high
  • Children younger than 5 years old who have a positive TB skin test
  • People who work with, or are part of, groups with high rates of infection, such as the homeless, IV drug users, or confined populations, such as hospitalized patients, prisoners, and residents of nursing homes
  • People with weakened immune systems such as:
    • Those with HIV infection
    • Those with chronic underlying conditions, including diabetes and kidney disease
    • Organ transplant recipients and others on immunosuppressant drugs
    • Pregnant women
    • The elderly
  • People who use tobacco

Signs and Symptoms

A latent TB infection does not cause symptoms. A person may have a latent TB infection for years without knowing it. It is usually detected when he or she has a positive IGRA blood test or TB skin test.

The classic symptoms of active TB disease in the lungs (pulmonary TB) include:

  • Chronic cough, sometimes with bloody sputum
  • Fever, chills
  • Night sweats
  • Unexplained weight loss
  • Weakness
  • Chest pain

Elderly people and those with weakened immune systems may not have these symptoms, yet they are at high risk of spreading TB to others.

When a TB infection occurs outside of the lungs (extrapulmonary disease), symptoms can vary depending on the site that is infected. It may cause few noticeable symptoms or a wide range, including:

  • Back pain and paralysis (spinal TB)
  • Weakness due to anemia (TB in the bone marrow)
  • Joint pain
  • Pain associated with the reproductive system or urinary tract and possibly resulting in infertility
  • Abdominal pain
  • Fever and shortness of breath (TB in the pericardium or miliary TB, which occurs when M. tuberculosis infects multiple organs)
  • Altered mental state, headache, and coma (TB in the brain and/or central nervous system, meningitis)

All of these symptoms may also be seen in a variety of other conditions. A diagnosis of active tuberculosis depends on the positive identification of Mycobacterium tuberculosis in the body fluids or tissues.


Screening Tests
Testing for Mycobacterium tuberculosis infection may begin with an IGRA TB blood test or a TB skin test. These screening tests are not diagnostic; they do not tell whether a person has latent TB or an active infection. Additional exams and tests (see Tests to Diagnose Active TB below) must be performed in follow up to a positive screening result.

TB screening is not used as a general screening test for all people but is targeted at those who are at a high risk for contracting the disease and those who have signs and symptoms consistent with an active TB infection. TB screening may also be done as part of a physical examination prior to starting school or a new job. There are two types of tests used to screen people at high risk for TB; usually only one of the tests is performed:

  • The tuberculin skin test (TST) is performed by injecting a small amount a substance called purified protein derivative (PPD) just under the skin on a person’s forearm. The person must return to the healthcare provider’s office 2 or 3 days after the PPD is injected so the injection site can be examined. If the person is infected with M. tuberculosis, a firm red bump will form at the injection site.
  • The interferon gamma release assay (IGRA) is a blood test that measures how strongly a person’s immune system reacts to specific TB antigens.

Tests to Diagnose Active TB
Acid-fast bacilli (AFB) testing can be used to identify and confirm active infection with M. tuberculosis as well as other Mycobacterium species. (Mycobacteria are called acid-fast bacilli because they are rod-shaped bacteria (bacilli) that can be seen under the microscope following a staining procedure in which the bacteria retain the color of the stain after an acid wash (acid-fast).) One or more of these tests may be performed when a person has signs and symptoms or TB disease or screened positive for TB infection.

Usually three sputum samples are collected early in the morning on different days. If the affected person is unable to produce sputum, a bronchoscope may be used to collect fluid during a procedure called a bronchoscopy. In children, gastric washings/aspirates may be collected. Depending on symptoms, urine, an aspirate from the site of suspected infection, cerebrospinal fluid (CSF), other body fluids, or biopsied tissue samples may be submitted for AFB smear and culture.

  • AFB smear — a microscopic examination of a specimen that has been stained to detect acid-fast bacteria, such as M. tuberculosis. This test can provide probable (presumptive) results within a few hours. It is a valuable tool in helping make decisions about treatment while culture results are pending.
  • Molecular tests for TB (nucleic acid amplification test, NAAT) — detect the genetic components of TB bacteria in a sputum sample and are often done when the AFB smear is positive or TB is highly suspected. Like AFB smears, NAATs can provide a presumptive diagnosis, which can aid in the decision of whether to begin treatment before culture results are available. Results of NAAT are typically available several hours after a sample is collected. One type of NAAT detects within two hours the presence of M. tuberculosis and determines if it is resistant to rifampin, one of the most commonly prescribed drugs used to treat TB. However, NAAT testing does not replace AFB cultures. All samples submitted for AFB testing should be cultured to ensure that any mycobacteria that are present are available for further testing, according to the Centers for Disease Control and Prevention.
  • AFB cultures to grow the bacteria are set up at the same time as the AFB smears. Though more sensitive than AFB smears, results of cultures may take days to several weeks.
  • Susceptibility testing on the acid-fast bacteria grown in the cultures that are positive will determine the bacteria’s susceptibility or resistance to drugs most commonly used to treat TB. Depending on the method used, results may be available in 7 days or can take several weeks. There are molecular tests available that can also be used to detect specific genes in the DNA of the bacteria that confer resistance to certain drugs.

Other Laboratory Tests

  • The adenosine deaminase (ADA) test is not a diagnostic test, but it may be used along with other tests to help determine whether a person has a TB infection in the lining of the lungs (pleurae). Pleural fluid presents a unique problem with detecting M. tuberculosis because there may be a large volume of fluid with a very low number of bacteria present. Though the ADA test is not definitive, it is a rapid test and may be elevated even when there are few bacteria present. ADA results may be used to help guide treatment until results from a culture are available.
  • A culture method called microscopic-observation drug-susceptibility (MODS) assay takes only about 7 days to diagnose TB and detects bacterial resistance to antibiotics. It can recognize the presence of TB bacteria much more quickly than traditional culture and can help healthcare providers diagnose and treat the disease at an earlier stage. It has the potential to help control the spread of TB in resource-limited countries, especially those in which HIV infection and TB are prevalent.

Non-Laboratory Tests
X-rays or CT scans are often performed as a follow-up to positive tuberculin skin or IGRA tests to look for signs of Mycobacterium tuberculosis in the lungs and help determine whether a person has active tuberculosis disease or a latent TB infection. Infection with TB can cause a number of characteristic findings on x-rays, including cavities (holes) and calcification in organs such as the lungs and kidneys. More information on radiological tests can be found at RadiologyInfo.org.


Prevention of the spread of TB lies primarily in identifying, isolating, and treating those who have it before they pass it on to others.

A vaccine, called BCG (Bacille Calmette-Guérin), is routinely administered in parts of the world where TB is common, although studies have shown that this vaccine will not prevent every case of TB. People who have been vaccinated with BCG will have a positive TB skin test, which eliminates the use of the skin test as an indicator of a recent TB infection. The incidence of TB in the U.S. is low, so U.S. health authorities do not recommend the use of the BCG vaccine.

Early Detection
Early detection depends on identifying those at risk and testing them at regular intervals for latent TB infection. It also depends on recognizing, diagnosing, and treating those who progress to active tuberculosis.

Treatment of Latent TB
People with latent TB may go on to develop an active infection, so they are treated to prevent them from getting TB disease. Currently available treatments for latent TB infection may reduce a person’s risk of developing active TB disease by 60-90%.

It is very important to follow the treatment regimen exactly as prescribed to ensure that all of the TB bacteria are killed. With the shorter courses of treatment, people may be more likely to take all their medication and the risk of side effects is reduced.

Active Tuberculosis
Once M. tuberculosis has been positively identified, a treatment program that involves taking several different antibiotics for several months will be recommended. The choice of medications and length of treatment will depend on the person’s age, overall health, possible drug resistance, and the location of the infection.

People with HIV infection who are diagnosed with active TB may require a unique drug regimen. One of the antibiotics, rifampin, is known to interfere with some of the antiretroviral drugs that are used in the treatment of HIV infection, so a different TB drug may be prescribed.

Although symptoms will often go away after several weeks, it is crucial that the infected person continue to take the drugs for the entire time period prescribed to ensure that all of the TB bacteria are killed. If bacteria remain in the body, the TB can come back (recur). Recurrent infection is more likely to be resistant to the first-line drugs, requiring treatment for several more months with drugs that have more side effects.

The health community strongly recommends that those with active tuberculosis participate in directly observed therapy (DOT). This involves taking the medication each day, or several days a week, under the supervision of medical personnel. This increases patient compliance with treatment and decreases the number of people who have to be treated again because their TB has returned.

Those who have been exposed to or diagnosed with TB that is resistant to one or both of the first-line drugs, rifampin and isoniazid (multidrug-resistant TB, MDR-TB), are prescribed a regimen utilizing second-line drugs.

View Sources

Sources Used in Current Review

Herchline TE, Amorosa JK. (2015 22 October, Updated.) Tuberculosis. Available online at http://emedicine.medscape.com/article/230802-overview. Accessed on January 2016.

World Health Organization. (2015 October, Updated.) Tuberculosis Fact Sheet. Available online at http://www.who.int/mediacentre/factsheets/fs104/en/. Accessed on January 2016.

U.S. Centers for Disease Control and Prevention. (2015 September, Updated.) Trends in Tuberculosis, 2014. Available online at http://www.cdc.gov/tb/publications/factsheets/statistics/tbtrends-2014.pdf. Accessed January 2016.

U.S. Centers for Disease Control and Prevention. (2013 April 16, Updated.) TB in Specific Populations. Available online at http://www.cdc.gov/tb/topic/populations/. Accessed January 2016.

Diel R, Loddenkemper R, Meywald-Walter K, Niermann S, Niehaus A. Predictive Value of a Whole Bood IFN-γ Assay for the Development of Active Tuberculosis Disease After Recent Infection with Mycobacterium tuberculosis. American Journal of Respiratory and Critical Care Medicine. 2008;177:1164-1170.

Diel R, Loddenkemper R, Niermann S, Meywald-Walter K, Nienhaus A. Negative and Positive Predictive Value of a Whole-blood Interferon-γ Release Assay for Developing Active Tuberculosis. American Journal of Respiratory and Critical Care Medicine. 2011;183:88-95.

Shah NS, Moodley P, Barbaria P, et al. Rapid Diagnosis of Tuberculosis and Multidrug Resistance by the Microscopic-Observation Drug-Susceptibility Assay. Am J Respir Crit Care Med. 2011;183:1427–1433.

U.S. Food and Drug Administration. (FDA News Release 2013, 25 July.) FDA Permits Marketing of First U.S. Test Labeled for Simultaneous Detection of Tuberculosis Bacteria and Resistance to the Antibiotic Rifampin. Available online at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm362602.htm. Accessed January 2016.

World Health Organization. (2014 October.) Latent Tuberculosis Infection. Available online at http://www.who.int/tb/publications/ltbi_factsheet_161014.pdf?ua=1. Accessed January 2016.

Mayo Clinic Staff. (2014 August 1, Updated.) Tuberculosis. Available online at http://www.mayoclinic.org/diseases-conditions/tuberculosis/basics/treatment/con-20021761?p=1. Accessed on January 2016.

U.S. Centers for Disease Control and Prevention. (2014 February 7, Updated.) Treatment for Latent TB Infection. Available online at http://www.cdc.gov/tb/topic/treatment/ltbi.htm. Accessed January 2016.

Centers for Disease Control and Prevention. Factsheet: A New Tool to Diagnose Tuberculosis: The Xpert MTB/RIF Assay. Available online at http://www.cdc.gov/tb/publications/factsheets/PDF/XpertMTB-RIFAssayFactSheet_Final.pdf. Accessed February 2016.

Sources Used in Previous Reviews

Thomas, Clayton L., Editor (1997). Taber’s Cyclopedic Medical Dictionary. F.A. Davis Company, Philadelphia, PA [18th Edition].

Pagana, Kathleen D. & Pagana, Timothy J. (2001). Mosby’s Diagnostic and Laboratory Test Reference 5th Edition: Mosby, Inc., Saint Louis, MO.

Heimerdinger, M. (2000). Tuberculosis. ACP-ASIM [On-line session report]. Available online at http://www.acponline.org/vas2000/sessions/tb.htm.

Kirchner, J. (2000 February 1). Do Sputum Smears Positive for AFB Signify Treatment Failure? American Family Physician [On-line journal]. Available online at http://www.aafp.org/afp/20000201/tips/25.html.

Jerant, A. et.al. (2000 May 1). Identification and Management of Tuberculosis. American Family Physician [On-line journal]. Available online at http://www.aafp.org/afp/20000501/2667.html.

Sadovsky, R. (2001 May 15). Making the Diagnosis of Tuberculosis in Children. American Family Physician [On-line journal]. Available online at http://www.aafp.org/afp/20010515/tips/9.html.

Centers for Disease Control and Prevention (CDC) (2002 August 13, Reviewed). Frequently Asked Questions, Questions and Answers about TB. National Center for HIV, STD and TB Prevention Division of Tuberculosis Elimination [On-line information]. Available online at http://www.cdc.gov/nchstp/tb/faqs/qa.htm.

Tuberculosis. The Merck Manual of Medical Information–Home Edition [On-line information]. Available online at http://www.merck.com/pubs/mmanual_home/sec17/181.htm.

Tan, L.J. (2000 June 28, Updated). ATS/CDC Statement Revises Treatment and Testing for Latent TB Infection. American Medical Association [On-line information]. Available online at http://www.ama-assn.org/ama/pub/article/1865-2125.html.

Mazurek, G. & Villarino, M. (2002 December 18 Updated). Guidelines for Using the QuantiFERON®-TB Test for Diagnosing Latent Mycobacterium tuberculosis Infection. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report [On-line report]. Available online at http://www.cdc.gov/mmwr/preview/mmwrhtml/di51cha1.htm.

Centers for Disease Control and Prevention (2002 March 23, Reviewed). TB and HIV Coinfection. National Center for HIV, STD and TB Prevention, Division of Tuberculosis Elimination [On-line information]. Available online at http://www.cdc.gov/nchstp/tb/pubs/TB_HIVcoinfection/default.htm.

Tuberculosis: Ancient Enemy Present Threat, “I must die”: Tuberculosis in History. NAIAD [On-line information]. Available online at http://www.niaid.nih.gov/newsroom/focuson/tb02/story.htm.

Tuberculosis (TB). American Lung Association [On-line information]. Available online at http://www.lungusa.org/diseases/lungtb.html.

(2002 January). American Lung Association® Fact Sheet: Tuberculosis. ALA [On-line information]. Available online at http://www.lungusa.org/diseases/tbfac.html.

(2002 January). American Lung Association® Fact Sheet: Tuberculosis Skin Test. ALA [On-line information]. Available online at http://www.lungusa.org/diseases/tbskinfac.html.

(2002 January). American Lung Association® Fact Sheet: Pediatric Tuberculosis. ALA [On-line information]. Available online at http://www.lungusa.org/diseases/pedtbfac.html.

NIAID (1999 December 1, Updated). The Global Burden of Tuberculosis. National Institute of Allergy and Infectious Diseases, National Institutes of Health [On-line publication]. Available online at http://www.niaid.nih.gov/publications/blueprint/page2.htm.

Tuberculin skin test. Hendrick Health System AccessMed [On-line information]. Available online at http://www.hendrickhealth.org/healthy/00069330.html.

Tuberculosis. Hendrick Health System AccessMed [On-line information]. Available online at http://www.hendrickhealth.org/healthy/00069340.html.

Mycobacteriology, Introduction to the Genus Mycobacteria. Microbiology Public Health for Northern Alberta, Bugs on the Web [On-line information]. Available online at http://www2.provlab.ab.ca/bugs/mycob/mbintro.htm.

Mycobacteriology, Acid-Fast Staining Procedures for Mycobacteria. Microbiology Public Health for Northern Alberta, Bugs on the Web [On-line information]. Available online at http://www2.provlab.ab.ca/bugs/mycob/afb_stain/afb_tutorial.htm.

Hall, G. (2001). Practical Microbiology, Update on Broth Media for the Isolation of Mycobacterium Species. Medscape from Infect Med 18(1):28-30, 2001 [On-line journal]. Available online at http://www.medscape.com/viewarticle/410131.

Tuberculin Purified Protein Derivative (Mantoux) Tubersol. Aventis Pasteur Inc. (Swiftwater, PA) [Package Insert].

(1996 October 28, Rev L). AccuProbe, Mycobacterium Tuberculosis Complex Culture Identification Test. Gen-Probe [Package Insert]. Available online at http://www.gen-probe.com/mtd.html.

(2006 November 3). Notice to Readers: Revised Definition of Extensively Drug-Resistant Tuberculosis. CDC MMWR 55(43);1176 [On-line information]. Available online at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5543a4.htm. Accessed December 10, 2006.

(2006 April). Tuberculosis: General Information. National Center for HIV, STD, and TB Prevention, Division of Tuberculosis Elimination Fact Sheet [On-line information]. Available online at http://www.cdc.gov/nchstp/tb/pubs/tbfactsheets/250010.htm. Accessed December 10, 2006.

(2006 March, Revised). Tuberculosis. World Health Organization [On-line information]. Available online at http://www.who.int/mediacentre/factsheets/fs104/en/index.html. Accessed December 10, 2006.

(2006 March). Tuberculosis. NIAID Fact Sheet [On-line information]. Available online at http://www.niaid.nih.gov/factsheets/tb.htm. Accessed December 10, 2006.

(2006 March 23). U.S. Tuberculosis cases at an all-time low in 2005, but drug resistance increasing. CDC Media Relations [On-line press release]. Available online at http://www.cdc.gov/od/oc/media/pressrel/fs060323.htm. Accessed December 10, 2006.

(2006 March). QuantiFERON-TB Gold Test. National Center for HIV, STD, and TB Prevention, Division of Tuberculosis Elimination Fact Sheet [On-line information]. Available online at http://www.cdc.gov/nchstp/tb/pubs/tbfactsheets/250103.htm. Accessed December 10, 2006.

(2006 April). Diagnosis of Tuberculosis Disease. National Center for HIV, STD, and TB Prevention, Division of Tuberculosis Elimination Fact Sheet [On-line information]. Available onlien at http://www.cdc.gov/nchstp/tb/pubs/tbfactsheets/250102.htm. Accessed December 10, 2006.

Palomino, J. (2006 April 21). Newer Diagnostics for Tuberculosis and Multi-Drug Resistant Tuberculosis. Medscape from Current Opinion in Pulmonary Medicine 12(3):172-178 [On-line journal]. Available online at http://www.medscape.com/viewarticle/529589.

Pagana, Kathleen D. & Pagana, Timothy J. (© 2007). Mosby’s Diagnostic and Laboratory Test Reference 8th Edition: Mosby, Inc., Saint Louis, MO. Pp 955-957.

Moore, DAJ et al. Microscopic-Observation Drug-Susceptibility Assay for the Diagnosis of TB. New England Journal of Medicine 2006;355:1539-1550.

Forbes BA, Sahm DF, Weissfeld AS, Bailey & Scott’s Diagnostic Microbiology 12th Edition: Mosby Elsevier, St. Louis, MO; 2007, Pp 478-508.

Centers for Disease Control and Prevention (CDC) fact sheets available online through http://www.cdc.gov:

Diagnosis of Tuberculous Disease: http://www.cdc.gov/tb/publications/factsheets/testing/diagnosis.htm

Trends in Tuberculosis, 2009: http://www.cdc.gov/tb/publications/factsheets/statistics/TBTrends.htm

Interferon Gamma Release assays: http://www.cdc.gov/tb/publications/factsheets/testing/IGRA.htm

Tuberculin Skin Test:  http://www.cdc.gov/tb/publications/factsheets/testing/skintesting.htm

Treatment of Latent TB: http://www.cdc.gov/tb/publications/factsheets/treatment/treatmentLTBI.htm Treatment of Drug-Susceptible Tuberculosis Disease in Persons Not Infected with HIV: http://www.cdc.gov/tb/publications/factsheets/treatment/treatmentHIVnegative.htm

Treatment of Drug-Susceptible Tuberculosis Disease in HIV-Infected Persons: http://www.cdc.gov/tb/publications/factsheets/treatment/treatmentHIVpositive.htm

Centers for Disease Control and Prevention. Updated Guidelines for the use of Nucleic Acid Amplification Tests in the Diagnosis of Tuberculosis. MMWR January 16, 2009 / 58(01); 7-10.  Available online at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5801a3.htm?s_cid=mm5801a3_e. Accessed January 2011.

Herchline T (December 17, 2010). Tuberculosis, eMedicine article. Available online at http://emedicine.medscape.com/article/230802-overview. Accessed January 2011.

(Jan. 29, 2009) Mayo Clinic. Tuberculosis. Available online at http://www.mayoclinic.com/health/tuberculosis/DS00372. Accessed January 2011.

(November 12, 2010) National Institute of Allergy and Infectious Diseases. Tuberculosis (TB). Available online at http://www.niaid.nih.gov/topics/tuberculosis/Pages/default.aspx. Accessed January 2011.

(November 2010) World Health Organization. Tuberculosis Fact Sheet. Available online at http://www.who.int/mediacentre/factsheets/fs104/en/index.html. Accessed January 2011.

Boehme C, et. al. Rapid Molecular Detection of Tuberculosis and Rifampin Resistance. N Engl J Med 2010; 363:1005-1015. Available online at http://www.nejm.org/doi/full/10.1056/NEJMoa0907847. Accessed January 2011.

Minion J, Leung E, Menzies D, Pai M. Microscopic-observation drug susceptibility and thin layer agar assays for the detection of drug resistant tuberculosis: a systematic review and meta-analysis. Lancet Inf Dis, 2010 Oct;10(10):688-98. Epub 2010 Aug 31. Available online at http://www.ncbi.nlm.nih.gov/pubmed/20813587. Accessed January 2011.